

Teva launches generic of Abilify, antipsychotic drug

30 April 2015 | News | By BioSpectrum Bureau

Teva launches generic of Abilify, antipsychotic drug



Singapore: Teva Pharmaceutical has launched the generic equivalent to Abilify, aripiprazole tablets, an atypical antipsychotic medication, are approved for the treatment of schizophrenia and for the acute treatment of manic and mixed episodes associated with bipolar I disorder.

"Our commitment at Teva is to make affordable, high-quality generic medicines available to millions of patients every day. We are pleased to launch generic Aripiprazole tablets and offer a generic treatment for patients suffering from schizophrenia and bipolar I disorder," said Mr Saggi Olafsson, president and CEO, global generic medicines, Teva.

Schizophrenia is a complex, long-term medical illness that affects a person's ability to think clearly, manage emotions, make decisions and relate to others. Approximately one percent of adult Americans live with schizophrenia. Schizophrenia is a chronic and disabling brain disorder that affects men and women equally, where people interpret reality abnormally. Symptoms of schizophrenia may include hallucinations, delusions, trouble with thinking and concentration, and lack of motivation.